United States · Platforms & data · Benzinga
Pfizer Pulls Menopause Hormone Therapy Premarin From Canadian Market
Detailed summary
Pfizer Inc. (NYSE:PFE) will reportedly no longer sell its hormone replacement therapy Premarin in Canada following an internal review, ending Canadian availability of both its…
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.benzinga.com)
